文献速递浆细胞疾病

真实世界人群中骨髓瘤恶性生物标志物(IMWG SLiM标准)的影响:来自澳大利亚和新西兰骨髓瘤及相关疾病登记处(ANZ MRDR)的临床特征、治疗与结局

The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
PubMed 文献 · Br J Haematol · 2024-07-04

该真实世界研究基于ANZ MRDR登记处2013至2023年3489例新诊断骨髓瘤患者,其中3232例符合CRAB标准(含1758例同时满足至少1项SLiM标准),257例仅符合SLiM标准。SLiM患者较CRAB患者无进展生存期(37.5 vs 32.2个月,HR 1.31)、总生存期(80.9 vs 73.2个月,HR 1.64)和PFS2(54.6 vs 40.3个月,HR 1.51)均更优。

要点

  • SLiM患者较CRAB患者无进展生存期更优(37.5 vs 32.2个月,HR 1.31)。
  • SLiM患者较CRAB患者总生存期更优(80.9 vs 73.2个月,HR 1.64)。
  • SLiM患者较CRAB患者PFS2更优(54.6 vs 40.3个月,HR 1.51)。

核心结论

  • 这些数据支持按SLiM标准更早启动治疗。
  • SLiM患者较CRAB患者生存结局更优,突显在解读诱导治疗和首次复发治疗结局时定义这些亚组的重要性。

研究设计与样本

  • 该研究为真实世界研究,使用澳大利亚和新西兰骨髓瘤及相关疾病登记处(ANZ MRDR)数据。
  • 纳入2013年至2023年新诊断的3489例患者,其中3232例由CRAB标准诊断(CRAB患者,包括1758例同时满足至少1项SLiM标准),257例由SLiM标准诊断(SLiM患者)。

主要发现

  • CRAB患者R-ISS分期更高、体能状态更低,而细胞遗传学风险无差异。
  • SLiM患者较CRAB患者无进展生存期更优(37.5 vs 32.2个月,HR 1.31 [1.08-1.59],p=0.003)。
  • SLiM患者较CRAB患者总生存期更优(80.9 vs 73.2个月,HR 1.64 [1.26-2.13],p<0.001)。
  • SLiM患者较CRAB患者PFS2更优(54.6 vs 40.3个月,HR 1.51 [1.22-1.86],p<0.001)。
  • 34%的CRAB患者未表现出SLiM特征,浆细胞与轻链标准对PFS的影响无差异。

临床怎么用

  • 这些数据支持按SLiM标准更早启动治疗。
  • SLiM患者较CRAB患者生存结局更优,突显在解读诱导治疗和首次复发治疗结局时定义这些亚组的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A decade after International Myeloma Working Group (IMWG) biomarkers (SLiM criteria) were introduced, this real-world study examined their impact on diagnosis, therapy and outcomes in myeloma. Using the ANZ MRDR, 3489 newly diagnosed patients from 2013 to 2023, comprising 3232 diagnosed by CRAB ('CRAB patients', including 1758 who also satisfied ≥1 SLiM criteria) and 257 by SLiM ('SLiM patients') criteria were analysed. CRAB patients had higher R-ISS and lower performance status, with no difference in cytogenetic risk. SLiM patients had improved progression-free survival (PFS, 37.5 vs. 32.2 months, hazard ratio [HR] 1.31 [1.08-1.59], p = 0.003), overall survival (80.9 vs. 73.2 months, HR 1.64 [1.26-2.13], p < 0.001) and PFS2 (54.6 vs. 40.3 months, HR 1.51 [1.22-1.86], p < 0.001) compared with CRAB patients, partially explained by earlier diagnosis, with no differential impact between the plasma cell and light-chain criteria on PFS. However, 34% of CRAB patients did not manifest SLiM characteristics, raising the possibility that SLiM features are associated with different biological behaviours contributing to a better prognosis, for example, improved PFS2 in SLiM patients suggested less disease resistance at first relapse. These data support earlier initiation of therapy by SLiM. The superior survival outcomes of SLiM versus CRAB patients highlight the importance of defining these subgroups when interpreting therapeutic outcomes at induction and first relapse.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ho PJ, Moore E, Wellard C, et al. The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). Br J Haematol. 2024. PMID: 38965706. doi:10.1111/bjh.19624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。